Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers

Nenhuma Miniatura disponível
Data
2008-02-01
Autores
Sader, Helio Silva [UNIFESP]
Watters, A. A.
Fritsche, T. R.
Jones, R. N.
Orientadores
Tipo
Resenha
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Daptomycin is a cyclic lipopeptide with potent bactericidal activity against Gram-positive organisms and has been approved by the United States Food and Drug Administration for the treatment of Staphylococcus aureus bacteremia and infectious endocarditis (right-side). We evaluated the activity of daptomycin against bloodstream infection S. aureus strains from 4,799 patients hospitalized in 32 medical centers (12 European countries, Turkey and Israel) with bloodstream infections (BSI) during a 5-year period (2002-2006). Intravenous catheters were the source of infection in 15% of cases, and those strains were analyzed separately. All strains were susceptibility tested by reference broth microdilution methods utilizing calcium supplementation (50 mg/L) when testing daptomycin. Bactericidal activity of daptomycin and vancomycin were evaluated against a subset of 50 randomly selected strains. Daptomycin (MIC (50/90), 0.25/0.5 mg/L), vancomycin (MIC50/90, 1/1 mg/L), and linezolid (MIC50/90, 2/2 mg/L), were highly active (>99.9% susceptibility) against the strains evaluated; and daptomycin was the most potent (lowest MIC90) among these compounds. Resistance rates to oxacillin and levofloxacin were generally elevated, especially when an intravenous catheter was the source of infection.
Descrição
Citação
Journal Of Chemotherapy. Florence: Esift Srl, v. 20, n. 1, p. 28-32, 2008.
Coleções